ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

被引:10
|
作者
Meyer, K
Voss, E
Neidlein, R
Kühnle, HF
Pill, J
机构
[1] Boehringer Mannheim GmbH, Therapeut Res, D-6800 Mannheim, Germany
[2] Univ Heidelberg, Inst Pharmazeut Chem, D-6900 Heidelberg, Germany
关键词
omega-substituted alkyl carboxylic acids; insulin sensitizer; lipid lowering;
D O I
10.1016/S0223-5234(99)80029-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In screening experiments certain omega-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated C-14-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic and lipid-lowering properties in genetically diabetic ob/ob mice demonstrated the in vivo relevance of the insulin-potentiating effects seen in vitro. The chemical structures of the w-substituted alkyl carboxylic acids with insulin-potentiating effects correspond to the general formula ring-spacer-COOH. A close structure-activity relationship was observed. The most potent compound in ob/ob mice was 3e, which normalized blood glucose as well as hyperinsulinaemia and lowered serum triglycerides and cholesterol by 52% and 37%, respectively. On the basis of these results, omega-substituted alkyl carboxylic acids are interesting as a new class of oral antidiabetic agents with insulin-sensitizing and lipid-lowering activity. (C) Elsevier, Paris.
引用
收藏
页码:775 / 787
页数:13
相关论文
共 50 条
  • [1] w-substituted alkyl carboxylic acids as novel antidiabetic and lipid lowering agents
    不详
    DIABETES OBESITY & METABOLISM, 1999, 1 (02): : 122 - 123
  • [2] Lipid-Lowering Agents
    Ewang-Emukowhate, Mfon
    Wierzbicki, Anthony S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 18 (05) : 401 - 411
  • [3] MECHANISMS OF LIPID-LOWERING AGENTS
    SIRTORI, CR
    MANZONI, C
    LOVATI, MR
    CARDIOLOGY, 1991, 78 (03) : 226 - 235
  • [4] Lipid-Lowering Agents and Hepatotoxicity
    Demyen, Michael
    Alkhalloufi, Kawtar
    Pyrsopoulos, Nikolaos T.
    CLINICS IN LIVER DISEASE, 2013, 17 (04) : 699 - +
  • [5] PRESCRIBING LIPID-LOWERING AGENTS
    WHEATLEY, G
    BRITISH JOURNAL OF GENERAL PRACTICE, 1995, 45 (395): : 329 - 329
  • [6] Discontinuing lipid-lowering agents
    Davis, George F.
    JOURNAL OF PALLIATIVE MEDICINE, 2006, 9 (03) : 619 - 619
  • [7] New lipid-lowering Agents
    Sinning, David
    Landmesser, Ulf
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (02) : 92 - 101
  • [8] Lipid-lowering agents and myopathy
    Wortmann, RL
    CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (06) : 643 - 647
  • [9] Lipid-lowering agents, hypothyroidism and rhabdomyolysis
    Iglesias, GP
    Sanjuán, JAG
    González, CG
    Sánchez, PS
    REVISTA CLINICA ESPANOLA, 2000, 200 (04): : 236 - 237
  • [10] Lipid-lowering agents for nephrotic syndrome
    Kong, Xiangyu
    Yuan, Hao
    Fan, Junming
    Li, Zi
    Wu, Taixiang
    Jiang, Lanhui
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):